bimekizumab
ucb pharmaceuticals
['axspa', 'bimekizumab']
bimekizumab shows sustained efficacy to 52 wks - phase 3 data in radiographic and non-radiographic no new safety concerns new moa: inhibits both il-17 a + f presentation by #acr22 #axspa
Rheumatologist | Physician |  Portsmouth Hospitals University NHS Trust UK | Views my own | Re-tweets do not mean endorsement | Mainly clinical news/updates